ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2064

Kinematics Underlying IBM-induced Dysphagia

Kevin Renz Ambrocio1, Vaidehi Kothari1, Rohit Aggarwal2, Anna Miles3, James L. Coyle1, Eaman Alhassan4, Sandra Stinnett1, David Lacomis1, Lea Sayce1 and Kendrea (Focht) Garand1, 1University of Pittsburgh, Pittsburgh, PA, 2University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA, 3The University of Auckland, Auckland, New Zealand, 4University of Pittsburgh Medical Center, Pittsburgh, PA

Meeting: ACR Convergence 2025

Keywords: Myopathies, Myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2052–2078) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Dysphagia remains a key contributor to mortality in IBM due to its connection with aspiration pneumonia and malnutrition (Shelly et al., 2021). Compared to other IIMs, IBM increases the odds of acquiring aspiration pneumonia and non-oral means of nutrition 3-fold (Ma et al., 2023). Yet, dysphagia kinematics in IBM are ill-defined, possibly leading to under-detection, misdiagnosis, and inappropriate dysphagia treatment (Ambrocio et al., 2023). Our study aimed to profile the kinematics underlying dysphagia in IBM using standardized and validated assessment methods and identify clinical predictors of dysphagia severity.

Methods: We conducted a prospective, cross-sectional study involving 15 adults with IBM (9 males) suspected of dysphagia. They had a mean age of 72.7 years (SD=5.9) and met the European Neuromuscular Center diagnostic criteria (Lilleker et al., 2024) and ACR classification (Lundberg et al., 2017). Their mean IBM Functional Rating Scale (IBMFRS) score and disease duration were 26.9 (SD=5.5) and 8.5 years (SD=3.8), respectively. Participants underwent a modified barium swallow study following the Modified Barium Swallow Impairment Profile (MBSImP) protocol, including 12 bolus tasks ranging from thin to highly thick liquids and a solid (Martin-Harris et al., 2008). We analyzed the images using MBSImP ratings, yielding Overall Impression (OI), Oral Total (OT), and Pharyngeal Total (PT) scores across 17 oral, pharyngeal, and esophageal kinematic components. We compared participants’ OI, OT, and PT scores with data from age- and sex-matched healthy controls in a normative database (Garand et al., 2022). Mann-Whitney U tests compared OI, OT, and PT scores between groups. We analyzed dysphagia severity using the Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) (Hutcheson et al., 2022). Univariate ordinal logistic regressions estimated the impact of OT and PT scores, age, sex, IBMFRS scores, and disease duration on DIGEST grades.

Results: Compared to controls, the IBM group had significantly higher (worse) OI scores for tongue motion, soft palate elevation, pharyngeal stripping, pharyngoesophageal segment opening, pharyngeal residue, and esophageal clearance, each p< .05, with large effects ranging from r=.51-.91 (Table 1). The IBM group had significantly higher (worse) OT (p=.001, r=.62) and PT (p=.013, r=.50) scores than controls, with large effects (Table 2). One participant had a normal DIGEST grade, but the rest spanned from mild to severe dysphagia. Only PT scores predicted DIGEST grades, with higher PT scores significantly linked to greater dysphagia severity, p=.031, OR=2.16 (Figure 1).

Conclusion: Participants with IBM exhibited kinematic deficits across swallowing phases. Surrogate kinematic markers for pressure generation and bolus propulsion mechanics were most impaired, which may be valuable for predicting dysphagia severity in IBM. Our study demonstrates the use of robust swallowing metrics to quantify and obtain a nuanced phenotypic dysphagia profile for IBM, representing an improvement over prior studies. Such findings facilitate targeted dysphagia treatment, precise symptom monitoring, and early identification of people with IBM at risk of dysphagia.

Supporting image 1

Supporting image 2

Supporting image 3Figure 1. DIGEST Dysphagia Severity Grade Regression.

The scatter plot shows the interaction between each participant’s PT score and DIGEST dysphagia severity grade, while the line represents the overall trend of the fitted regression model. This trend illustrates that higher (worse) PT scores are generally associated with higher (worse) DIGEST dysphagia severity grades. DIGEST severity grade interpretation: 0=normal, 1=mild, 2=moderate, 3=severe.


Disclosures: K. Ambrocio: None; V. Kothari: None; R. Aggarwal: Alexion, 2, ANI Pharmaceuticals, 2, Argenx, 2, Artasome, 2, AstraZeneca, 2, Boehringer-Ingelheim, 2, 5, Bristol-Myers Squibb(BMS), 2, 5, CabalettaBio, 2, Capella, 2, Capstanx, 2, CSL Behring, 2, EMD Serono, 2, 5, Galapagos, 2, Horizon Therapeutics, 2, I-Cell, 2, Immunovant, 2, Janssen, 2, 5, Kezar, 2, Kyverna, 2, Lilly, 2, Manta Medicines, 2, Nkarta, 2, Novartis, 2, Octapharma, 2, Pfizer, 2, 5, Priovant, 2, 5, Teva, 2, Tourmaline Bio, 2, UCB, 2, Verismo Therapeutics, 2; A. Miles: None; J. Coyle: None; E. Alhassan: None; S. Stinnett: None; D. Lacomis: UpToDate, 9; L. Sayce: None; K. (Focht) Garand: None.

To cite this abstract in AMA style:

Ambrocio K, Kothari V, Aggarwal R, Miles A, Coyle J, Alhassan E, Stinnett S, Lacomis D, Sayce L, (Focht) Garand K. Kinematics Underlying IBM-induced Dysphagia [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/kinematics-underlying-ibm-induced-dysphagia/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/kinematics-underlying-ibm-induced-dysphagia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology